Verification evidence is still being completed.
PDF / print export
NMD Pharma A/S
Aarhus, Denmark
- Verified lead
- Thomas Holm Pedersen
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Co-Founder and Chief Executive Officer
- 2026 technical specialization
- Neuromuscular Therapeutics, ClC-1 Chloride-Channel Inhibitors, and Phase 2 Myasthenia Gravis
- Review cycle
- 24 April 2026
- Full address
- Palle Juul-Jensens Boulevard 82, 8200 Aarhus N, Denmark
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- NMD Pharma management-team page naming Thomas Holm Pedersen as Co-Founder and CEO.
- Editorial note
- Aarhus clinical-stage neuromuscular biotech with named co-founder CEO since 2015, Phase 2 NMD670 program, and multi-site Aarhus-Copenhagen-Cambridge operations.
Neuromuscular Therapeutics, ClC-1 Chloride-Channel Inhibitors, and Phase 2 Myasthenia Gravis
Public management-team CEO disclosure, Heidrick and Struggles podcast interview, Phase 2 program documentation
Aarhus clinical-stage neuromuscular biotech with named co-founder CEO since 2015, Phase 2 NMD670 program, and multi-site Aarhus-Copenhagen-Cambridge operations.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated07 Jul 2026, 01:10
Company profile · Aarhus, Denmark
NMD Pharma A/S
Neuromuscular Therapeutics, ClC-1 Chloride-Channel Inhibitors, and Phase 2 Myasthenia Gravis · Clinical-stage small-molecule development
Verified 24 Apr 2026 · 3 sources
API SynthesisCommercial
Aarhus clinical-stage neuromuscular biotech with named co-founder CEO since 2015, Phase 2 NMD670 program, and multi-site Aarhus-Copenhagen-Cambridge operations.
Contact & location
- Website
- nmdpharma.com
- Company page
- Lead
- Thomas Holm Pedersen (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (2mo ago)
- Scale
- Clinical-stage small-molecule development
- Capabilities
- ClC-1 Chloride-Channel Small-Molecule Discovery · Phase 2 Myasthenia Gravis Program · Multi-Site Operations (Aarhus, Copenhagen, Cambridge MA)
- Founded
- 2015
- Headcount
- 11-50
Neuromuscular Therapeutics, ClC-1 Chloride-Channel Inhibitors, and Phase 2 Myasthenia Gravis
Aarhus clinical-stage neuromuscular biotech with named co-founder CEO since 2015, Phase 2 NMD670 program, and multi-site Aarhus-Copenhagen-Cambridge operations.
Editorial note
NMD Pharma anchors Danish neuromuscular drug development with a named co-founder CEO since 2015, a Phase 2 NMD670 program in myasthenia gravis, and satellite offices in Copenhagen and Cambridge MA.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Verification details
Clinical profileSTATUS: VERIFIED APRIL 2026
Thomas Holm Pedersen
Co-Founder and Chief Executive Officer
Full addressPalle Juul-Jensens Boulevard 82, 8200 Aarhus N, Denmark
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
NMD Pharma contact page listing Palle Juul-Jensens Boulevard 82 in Aarhus.
Open sourceClinical-stage small-molecule development
Aarhus, Denmark. Neuromuscular Therapeutics, ClC-1 Chloride-Channel Inhibitors, and Phase 2 Myasthenia Gravis. Review completed on 24 Apr 2026.
Danish Medicines Agency, EMA, and FDA for clinical-stage oversight
Public management-team CEO disclosure, Heidrick and Struggles podcast interview, Phase 2 program documentation
Capabilities
ClC-1 Chloride-Channel Small-Molecule Discovery
Phase 2 Myasthenia Gravis Program
Multi-Site Operations (Aarhus, Copenhagen, Cambridge MA)
Sources
The official sources used to verify this profile.
Infrastructure
Small-molecule discovery workflow
Clinical trial operations
Multi-site coordination
Certifications
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Review log
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
Frequently asked questions
- Where is NMD Pharma A/S located?
- NMD Pharma A/S operates from Palle Juul-Jensens Boulevard 82, 8200 Aarhus N, Denmark, Aarhus, Denmark.
- Who runs NMD Pharma A/S?
- NMD Pharma A/S is led by Thomas Holm Pedersen, Co-Founder and Chief Executive Officer. Verified 24 Apr 2026.
- What does NMD Pharma A/S do?
- Aarhus clinical-stage neuromuscular biotech with named co-founder CEO since 2015, Phase 2 NMD670 program, and multi-site Aarhus-Copenhagen-Cambridge operations. Core capabilities: ClC-1 Chloride-Channel Small-Molecule Discovery, Phase 2 Myasthenia Gravis Program, Multi-Site Operations (Aarhus, Copenhagen, Cambridge MA).
Editorial context
Related technical briefs
Briefs that name Aarhus as a covered market or city.